Molecular Partners (NASDAQ:MOLN) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of Molecular Partners (NASDAQ:MOLN) in a research report sent to investors on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $13.00 target price on the stock. HC Wainwright also issued estimates for Molecular Partners’ Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.64) EPS.

A number of other equities analysts have also recently issued reports on the company. JPMorgan Chase & Co. lowered their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $9.58.

Molecular Partners Trading Up 5.4%

Shares of NASDAQ MOLN traded up $0.21 during mid-day trading on Tuesday, reaching $4.21. 3,767 shares of the company’s stock were exchanged, compared to its average volume of 5,931. Molecular Partners has a twelve month low of $3.36 and a twelve month high of $5.35. The firm has a market capitalization of $170.16 million, a price-to-earnings ratio of -2.17 and a beta of 1.07. The business has a fifty day simple moving average of $4.24 and a 200 day simple moving average of $3.94.

Molecular Partners (NASDAQ:MOLN) last announced its earnings results on Thursday, October 30th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.05. Equities research analysts predict that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

Key Stories Impacting Molecular Partners

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright upgraded MOLN to a “Strong‑Buy” (research note by R. Burns). Upgrades from a sell‑side firm can spur buying interest and short‑term momentum in small‑cap biotech names. TickerReport: HC Wainwright Upgrade
• Positive Sentiment: HC Wainwright’s updated forecasts reduce expected full‑year losses vs. consensus: FY2026 EPS est. -$1.70 and FY2027 est. -$1.64 (consensus noted ~ -$1.93). Narrower losses imply a more bullish outlook on program progress, milestones or financing assumptions — a constructive signal for valuation and investor sentiment. MarketBeat: Analyst Estimates
• Neutral Sentiment: HC Wainwright published detailed quarterly EPS projections for 2026–2027 (Q1–Q4 2026: about -$0.41–0.44; Q1–Q4 2027: roughly -$0.45–0.39). These granular estimates update the firm’s model but are informational until paired with operational catalysts (clinical readouts, partnerships, or funding events). MarketBeat: Quarterly Estimates

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.